To investigate the effect of a low-dose oral contraceptive containing drospirenone/ethinylestradiol 3 mg/20 μg on endometrioma mean diameter.
Methods
Fifty women with sonographic diagnosis of ovarian endometrioma and at least 12 months of therapy with drospirenone/ethinylestradiol 3 mg/20 μg, without previous adnexal surgery, were selected for this retrospective study. Endometrioma mean diameter measured with transvaginal ultrasonography and endometriosis-associated symptoms evaluated by a visual analogue scale (VAS) score (0-10) were reported at therapy prescription (baseline) and after 6, 12 and 18 months of treatment. Main outcome measures were endometrioma mean diameters and endometriosis-associated symptoms variations during the follow-up; differences between cyclic and continuous regimen were also considered.
Results
A significant reduction in endometrioma mean diameter was observed during the follow-up. The reductions of mean diameter versus baseline values were significantly higher in continuous users than in cyclic users at 6 and 18 months of follow-up. No new endometriomas occurred. The dysmenorrhea VAS score significantly decreased during the follow-up.
Conclusions
Drospirenone/ethinylestradiol 3 mg/20 μg seems to be effective in reducing endometrioma mean diameter. The continuous regimen seems to be associated with a greater reduction than the cyclic one.
LiuX., YuanL., ShenF., ZhuZ., JiangH., GuoS.W.Patterns of and risk factors for recurrence in women with ovarian endometriomas.Obstet Gynecol.2007; 109(6): 1411–1420.
2.
JenkinsS., OliveD.L., HaneyA.F.Endometriosis: pathogenetic implications of the anatomic distribution.Obstet Gynecol.1986; 67(3): 335–338.
3.
BenagliaL., SomiglianaE., VercelliniP., AbbiatiA., RagniG., FedeleL.Endometriotic ovarian cysts negatively affect the rate of spontaneous ovulation.Hum Reprod.2009; 24(9): 2183–2186.
4.
HaradaT., MomoedaM., TaketaniY., HoshiaiH., TerakawaN.Low-dose oral contraceptive pill for dysmenorrhea associated with endometriosis: a placebo-controlled, double-blind, randomized trial.Fertil Steril.2008; 90(5): 1583–1588.
5.
Ruiz-FloresF.J., Garcia-VelascoJ.A.Is there a benefit for surgery in endometrioma-associated infertility?Curr Opin Obstet Gynecol.2012; 24(3): 136–140.
MuziiL., MaranaR., CaruanaP., CatalanoG.F., MarguttiF., PaniciP.B.Postoperative administration of monophasic combined oral contraceptives after laparoscopic treatment of ovarian endometriomas: a prospective, randomized trial.Am J Obstet Gynecol.2000; 183(3): 588–592.
8.
MuziiL., BellatiF., PalaiaI.Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part I: clinical results.Hum Reprod.2005; 20(7): 1981–1986.
9.
HartR.J., HickeyM., MaourisP., BuckettW.Excisional surgery versus ablative surgery for ovarian endometriomata.Cochrane Database Syst Rev.2008; 16: CD004992.
10.
MuziiL., BianchiA., CrocèC., ManciN., PaniciP.B.Laparoscopic excision of ovarian cysts: is the stripping technique a tissue-sparing procedure?Fertil Steril.2002; 77(3): 609–614.
11.
MuziiL., BellatiF., BianchiA.Laparoscopic stripping of endometriomas: a randomized trial on different surgical techniques. Part II: pathological results.Hum Reprod.2005; 20(7): 1987–1992.
12.
BenagliaL., SomiglianaE., VighiV., RagniG., VercelliniP., FedeleL.Rate of severe ovarian damage following surgery for endometriomas.Hum Reprod.2010; 25(3): 678–682.
13.
Garcia-VelascoJ.A., SomiglianaE.Management of endometriomas in women requiring IVF: to touch or not to touch.Hum Reprod.2009; 24(3): 496–501.
14.
KitajimaM., DefrèreS., DolmansM.M.Endometriomas as a possible cause of reduced ovarian reserve in women with endometriosis.Fertil Steril.2011; 96(3): 685–691.
15.
VercelliniP., TrespidiL., ColomboA., VendolaN., MarchiniM., CrosignaniP.G.A gonadotropin-releasing hormone agonist versus a low-dose oral contraceptive for pelvic pain associated with endometriosis.Fertil Steril.1993; 60(1): 75–79.
16.
VercelliniP., SomiglianaE., ViganòP., AbbiatiA., DaguatiR., CrosignaniP.G.Endometriosis: current and future medical therapies.Best Pract Res Clin Obstet Gynaecol.2008; 22(2): 275–306.
17.
VercelliniP., CrosignaniP., SomiglianaE., ViganòP., FrattaruoloM.P., FedeleL.'Waiting for Godot': a commonsense approach to the medical treatment of endometriosis.Hum Reprod.2011; 26(1): 3–13.
18.
CrosignaniP., OliveD., BergqvistA., LucianoA.Advances in the management of endometriosis: an update for clinicians.Hum Reprod Update.2006; 12(2): 179–189.
19.
MeresmanG.F., AugéL., BarañaoR.I., LombardiE., TesoneM., SueldoC.Oral contraceptives suppress cell proliferation and enhance apoptosis of eutopic endometrial tissue from patients with endometriosis.Fertil Steril.2002; 77(6): 1141–1147.
20.
VercelliniP., SomiglianaE., DaguatiR., ViganoP., MeroniF., CrosignaniP.G.Postoperative oral contraceptive exposure and risk of endometrioma recurrence.Am J Obstet Gynecol.2008; 198: 504.e.1–504.e.5.
21.
SeracchioliR., MabroukM., FrascàC.Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a randomized controlled trial.Fertil Steril.2010; 93(1): 52–56.
22.
RanaN., ThomasS., RotmanC., DmowskiW.P.Decrease in the size of ovarian endometriomas during ovarian suppression in stage IV endometriosis. Role of pre-operative medical treatment.J Reprod Med.1996; 41(6): 384–392.
23.
TsujiokaH., InoueY., EmotoM.The efficacy of pre-operative hormonal therapy before laparoscopic cystectomy of ovarian endometriomas.J Obstet Gynaecol Res.2009; 35(4): 782–786.
24.
MabroukM., SolfriniS., FrascàC.A new oral contraceptive regimen for endometriosis management: preliminary experience with 24/4-day drospirenone/ethinylestradiol 3 mg/20 mcg.Gynecol Endocrinol.2012; 28(6): 451–454.
25.
VercelliniP., FrontinoG., De GiorgiO., PietropaoloG., PasinR., CrosignaniP.G.Continuous use of an oral contraceptive for endometriosis-associated recurrent dysmenorrhea that does not respond to a cyclic pill regimen.Fertil Steril.2003; 80(3): 560–563.
26.
HuskissonE.C.Visual analogue scales. Pain measurement and assessment.Raven Press: New York; 1983: 33–37.
27.
Van HolsbekeC., Van CalsterB., GuerrieroS.Endometriomas: their ultrasound characteristics.Ultrasound Obstet Gynecol.2010; 35(6): 730–740.
28.
SavelliL.Transvaginal sonography for the assessment of ovarian and pelvic endometriosis: how deep is our understanding?Ultrasound Obstet Gynecol.2009; 33(5): 497–501.
29.
SokalskaA., TimmermanD., TestaA.C.Diagnostic accuracy of transvaginal ultrasound examination for assigning a specific diagnosis to adnexal masses.Ultrasound Obstet Gynecol.2009; 34(4): 462–470.
30.
KlippingC., DuijkersI., TrummerD., MarrJ.Suppression of ovarian activity with a drospirenone-containing oral contraceptive in a 24/4 regimen.Contraception.2008; 78(1): 16–25.
31.
DavisL., KennedyS.S., MooreJ., PrenticeA.Oral contraceptives for pain associated with endometriosis.Cochrane Database Syst Rev.2007; 18: CD001019.
32.
FauconnierA., ChapronC., DubuissonJ.B., VieiraM., DoussetB., BréartG.Relation between pain symptoms and the anatomic location of deep infiltrating endometriosis.Fertil Steril.2002; 78(4): 719–726.
33.
RomanH., TartaO., PuraI.Direct proportional relationship between endometrioma size and ovarian parenchyma inadvertently removed during cystectomy, and its implication on the management of enlarged endometriomas.Hum Reprod.2010; 25(6): 1428–1432.
